Quarterly ResultMay 5, 2026, 04:09 PM
Dianthus Therapeutics Q1 Results; $1.2B Cash, CAPTIVATE Early GO
AI Summary
Dianthus Therapeutics reported its Q1 2026 financial results and highlighted significant business achievements. The company announced an early GO decision in the claseprubart CIDP CAPTIVATE study and received Orphan Drug Designation for claseprubart in Myasthenia Gravis. Dianthus also strengthened its balance sheet by raising approximately $719 million in a public offering, resulting in $1.2 billion in cash, cash equivalents, and investments as of March 31, 2026, providing a runway into 2030. The net loss for Q1 2026 was $40.8 million, or $0.85 per share.
Key Highlights
- Early GO decision reached in claseprubart CIDP CAPTIVATE study with 20 confirmed responders.
- Claseprubart granted Orphan Drug Designation by FDA for Myasthenia Gravis.
- Phase 3 EMERGE trial for gMG on track to initiate in mid-2026; top-line results anticipated in 2H'28.
- Raised approximately $719 million in gross proceeds from an underwritten public offering.
- Cash, cash equivalents, and investments totaled approximately $1.2 billion as of March 31, 2026.
- Cash position provides expected runway into 2030.
- Q1 2026 Net Loss was $40.8 million, or $0.85 per share.
- Q1 2026 R&D expenses increased to $34.5 million from $27.0 million in Q1 2025.